Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, ...

Pfizer PFE reported second-quarter 2025 adjusted earnings per share of 78 cents, which comprehensively beat the Zacks ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended ...

Antibody-drug conjugates are a growing class of biopharmaceuticals that combine the precision of monoclonal antibodies with ...

The injectable production specialist has snapped up a 65-acre property with more than 300,000 square feet of usable space to ...

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line ...

Seagen’s Adcetris was trounced by Bristol-Myers Squibb’s Opdivo in a head-to-head trial in classical Hodgkin lymphoma (cHL) reported at ASCO – but there may be a way for the drug to bounce ...

A multidrug regimen containing brentuximab vedotin (BV, Adcetris) proved feasible for older patients with advanced classical ...

Hodgkin's lymphoma market size is expected to increase during the forecast period (2025–2034) owing to increasing incidence, advancements in ...

Pfizer PFE will report its second-quarter 2025 earnings on Aug. 5, before market open. The Zacks Consensus Estimate for sales ...